---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015635"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T19:50:51.870011+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protalix appoints Eliot Richard Forster as Chairman; Zeev Bronfeld retires

## Summary
- Forster appointed Chairman and independent director effective Sept 14, 2023; also joins Nominating Committee.
- Zeev Bronfeld retires as Chairman after nearly three decades; cites recent drug approval as transition point.
- Forster receives 10-year option for 85,715 shares vesting quarterly over 3 years and $70,000 annual fee.
- Forster is non-executive chairman of Avacta Group and director of Immatics NV; former CEO of F-Star Therapeutics.

## SEC filing metadata
- accession: 0001558370-23-015635
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/plx-20230912x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015635
- JSON: https://secwatch.observer/filing/0001558370-23-015635.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015635.txt

## Key facts
- Executive change
  Zeev Bronfeld retired as Chairman of the Board at Protalix BioTherapeutics, Inc..
  - Action: retired
  - Role: Chairman of the Board
  source text: Zeev Bronfeld, the Company’s current Chairman of the Board, has notified the Company of his retirement from the Company for personal reasons, effective as of the same date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm
- Executive change
  Eliot Richard Forster was appointed as Chairman of the Board at Protalix BioTherapeutics, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: On September 12, 2023, Protalix BioTherapeutics, Inc. (the “Company”) announced the appointment by its Board of Directors of Eliot Richard Forster, Ph.D. as Chairman of the Company’s Board of Directors effective as of September 14, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837023015635/0001558370-23-015635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.